This is the authors' abstract. We don't add key points for this paper.
Oxiperomide, a new dopamine-receptor antagonist, was found to decrease dyskinesias in patients with Parkinson's disease receiving levodopa or other dopamine agonists without necessarily increasing Parkinsonian symptoms. Oxiperomide also decreased spontaneous dyskinesias in those with tics and chorea and to a less extent in those with torsion dystonia, without necessarily causing Parkinsonism. These results provide evidence that more than one population of dopamine receptors exist in the extra pyramidal system, and encourage the search for selective dopamine antagonists.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bédard et al. (1978) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: